Vaccine Development Insights
Moncef emphasizes the importance of including high-risk groups in vaccine trials, ensuring that at least 40-45% of participants are from these populations. He remains focused on the scientific process, asserting that political timelines are irrelevant to vaccine safety and efficacy. Both express hope for a transparent data release and stress the continued need for public health measures like social distancing and mask-wearing until a vaccine is available.In this clip
From this podcast
Chasing Life
Safety vs Speed in the Race for a Vaccine
Related Questions